AARTIPHARMAarti Pharmalabs Limited

NSE · Healthcare · Small Cap · Mkt cap ₹10.4B · Vol 33.88M

₹3,464.66

▼ -2.73% today

Fetching live price…

God's Eye forensics

Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.

Piotroski F-Score

5/5

5

5 of 5 financial-health checks passed (4 checks need data this provider doesn't publish).

Altman Z-Score

Insufficient data

—

Needs total assets, operating profit and debt — not published for this listing yet.

Beneish (earnings quality)

Insufficient data

—

The full manipulation model needs two years of receivables, depreciation and accrual data, which isn't published for this listing.

Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.

Fundamental breakdown — raw ratios are free · fetching live data — showing modeled estimates for now

P/E Ratio (TTM)

Modeled

33.8x

Fairly priced

Contextual insight — DeepScreen Pro

PEG Ratio

Modeled

1.47

Fairly valued

Contextual insight — DeepScreen Pro

P/S Ratio

Modeled

9.94x

Rich sales multiple

Contextual insight — DeepScreen Pro

P/B Ratio

Modeled

8.82x

Typical for the sector

Contextual insight — DeepScreen Pro

EV/Revenue

Modeled

9.78x

Priced for exceptional growth

Contextual insight — DeepScreen Pro

EV/EBITDA

Modeled

25.0x

Fair

Contextual insight — DeepScreen Pro

ROE

Modeled

26.1%

Excellent shareholder returns

Contextual insight — DeepScreen Pro

ROA

Modeled

16.2%

Strong for asset-light

Contextual insight — DeepScreen Pro

ROCE

Modeled

24.9%

High-quality compounder

Contextual insight — DeepScreen Pro

Debt / Equity

Modeled

0.26x

Conservative balance sheet

Contextual insight — DeepScreen Pro

LT Debt / Equity

Modeled

0.13x

Very low structural debt

Contextual insight — DeepScreen Pro

Payout Ratio

Modeled

16%

Growth company — reinvesting most profit

Contextual insight — DeepScreen Pro

Operating Leverage

Modeled

3.08x

Profits amplify — both ways

Contextual insight — DeepScreen Pro

Company financials

EPS (TTM): ₹102.50
Revenue (TTM): ₹1.0B
Net margin: 29.4%
EBITDA margin: 39.1%
Earnings growth: 23%
Dividend yield: 0.47%
Payout ratio: 16%
Debt / equity: 0.26x

Live data hasn't loaded yet — figures shown are DeepScreen's modeled estimates.

AARTIPHARM live news

LIVE

Loading live headlines…